Results 31 to 40 of about 6,688,553 (311)

Mapping MAGE-A4 expression in solid cancers for targeted therapies

Frontiers in Oncology
Melanoma-associated antigen A4 (MAGE-A4) is a promising target for anticancer therapy. However, limited contemporary data are available on the details of MAGE-A4 protein expression in different cancer types.
Christin Habigt, Sylvie Rottey, Iben Spanggaard, Juanita S. Lopez, Elena Garralda, Emiliano Calvo, Oliver Bechter, Oliver Bechter, Jayesh Desai, Rachel Galot, Leena Gandhi, Florian Heil, Natascha Rieder, Ivan Dimitrov, Iris Martinez Quetglas, Christian Heichinger, Nino Keshelava, Andreas Roller   +17 more
doaj   +1 more source

CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies

Clinical and Translational Medicine, 2022
Background The CD47‐signal regulatory protein alpha (SIRPα) ‘don't eat me’ signalling axis is perhaps the most prominent innate immune checkpoint to date.
Renée Bouwstra, Tom vanMeerten, Edwin Bremer   +2 more
doaj   +1 more source

Patient selection for trials [PDF]

Multiple Sclerosis Journal, 2017
The last several decades have witnessed considerable progress in our understanding of the pathogenesis, refining diagnostic criteria, and identifying therapies of value for modifying the course of relapsing forms of multiple sclerosis. While the pace of progress has lagged for those with progressive phase disease, this now seems to be changing.
openaire   +2 more sources

Evaluation of triage methods used to select patients with suspected pandemic influenza for hospital admission: cohort study

Health Technology Assessment, 2010
Background: Triage methods are necessary in emergency departments to provide clinicians with a reliable method for determining each patient’s risk of adverse outcome.
S Goodacre, K Challen, R Wilson, M Campbell   +3 more
doaj   +1 more source

Adverse outcomes in nontrial like patients on commercial HeartMate 3 LVAD support

JHLT Open, 2023
Background: Patient selection for real-world use of HeartMate 3 left ventricular assist device (HM3 LVAD) differs from that of clinical trials. We assessed adverse-event rates between “nontrial like” (NTL) and “trial like” (TL) patients who underwent ...
Laura Coyle, APN, Colleen Gallagher, BSN, Nicole Graney, APN, Lisa Kukla, APN, Robin Paliga, APN, Kylie Hughes, APN, Rachel Pedersen, BA, Kathleen Schultz, APN, Adam JT Schuldt, MD, PhD, Nasir Sulemanjee, MD, Gregory P. Macaluso, MD, Sunil Pauwaa, MD, James Monaco, MD, Mark Dela Cruz, MD, William G. Cotts, MD, Nikhil Narang, MD, Patroklos S. Pappas, MD, Antone J. Tatooles, MD, Vinh Q. Chau, MD   +18 more
doaj   +1 more source

Optimizing patient selection for stereotactic ablative radiotherapy in patients with locally advanced pancreatic cancer after initial chemotherapy - a single center prospective cohort

Frontiers in Oncology, 2023
BackgroundThe role of stereotactic ablative radiation therapy (SABR) as local treatment option after chemotherapy for locally advanced pancreatic cancer (LAPC) is evolving.
D. Doppenberg, D. Doppenberg, D. Doppenberg, F. J. Lagerwaard, F. J. Lagerwaard, S. van Dieren, M. R. Meijerink, M. R. Meijerink, J. J. van der Vliet, J. J. van der Vliet, J. J. van der Vliet, M. G. Besselink, M. G. Besselink, G. van Tienhoven, G. van Tienhoven, E. Versteijne, E. Versteijne, B. J. Slotman, B. J. Slotman, J. W. Wilmink, J. W. Wilmink, G. Kazemier, G. Kazemier, A. M. E. Bruynzeel, A. M. E. Bruynzeel   +24 more
doaj   +1 more source

Limits to Patient Selection [PDF]

AMA Journal of Ethics, 2011
Patients can use Internet sources to select physicians; physicians who use patient databases to select or reject patients, however, cross a professional-ethical boundary. Virtual Mentor is a monthly bioethics journal published by the American Medical Association.
openaire   +2 more sources

Is There a Place for Somatostatin Analogues for the Systemic Treatment of Hepatocellular Carcinoma in the Immunotherapy Era?

Livers, 2022
Patients with advanced hepatocellular carcinoma (HCC) have a very limited survival rate even after the recent inclusion of kinase inhibitors or immune checkpoint inhibitors in the therapeutic armamentarium. A significant problem with the current proposed
Elias Kouroumalis, Ioannis Tsomidis, Argryro Voumvouraki   +2 more
doaj   +1 more source

Special Issue – July/August 2020: Sustaining a Focus on Human Experience in the Face of COVID-19 [PDF]

, 2020
At this critical time in our shared history, we are faced with a powerful challenge, the rapid impact of COVID-19 on our healthcare systems and community.
Journal, Patient Experience, Patient Experience Journal   +1 more
core   +1 more source

Patient selection for total ankle arthroplasty [PDF]

, 2017
Laurens W van der Plaat,1 Daniël Haverkamp2 1Department of Orthopaedic Surgery, Noordwest Ziekenhuisgroep, Alkmaar, the Netherlands; 2Slotervaart Center of Research and Education (SCORE), MC Slotervaart Hospital, Amsterdam, the Netherlands Abstract:
van der Plaat LW, Laurens van der Plaat, Haverkamp D, Daniel Haverkamp   +3 more
core   +1 more source